329 related articles for article (PubMed ID: 27572392)
1. Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.
Lu C; Zhang Y; Chen M; Zhong P; Chen Y; Yu J; Wu X; Wu J; Zhang J
Antimicrob Agents Chemother; 2016 Nov; 60(11):6619-6625. PubMed ID: 27572392
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery.
Zhang Y; Zhang J; Chen Y; Yu J; Cao G; Wu X; Chen M; Wu J; Zhao X
World Neurosurg; 2017 Feb; 98():525-531. PubMed ID: 27867128
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients.
Tsumura R; Ikawa K; Morikawa N; Ikeda K; Shibukawa M; Iida K; Kurisu K
J Chemother; 2008 Oct; 20(5):615-21. PubMed ID: 19028626
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of cerebrospinal fluid inhibitory titers of antibiotics, based on pharmacokinetic/pharmacodynamic parameters, in the treatment of bacterial meningitis.
Morikawa Y; Kitazato M; Morita T; Mizunaga S; Mitsuyama J
J Infect Chemother; 2009 Aug; 15(4):233-8. PubMed ID: 19688242
[TBL] [Abstract][Full Text] [Related]
10. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780
[TBL] [Abstract][Full Text] [Related]
12. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
[TBL] [Abstract][Full Text] [Related]
13. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
Germovsek E; Lutsar I; Kipper K; Karlsson MO; Planche T; Chazallon C; Meyer L; Trafojer UMT; Metsvaht T; Fournier I; Sharland M; Heath P; Standing JF;
J Antimicrob Chemother; 2018 Jul; 73(7):1908-1916. PubMed ID: 29684147
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
[TBL] [Abstract][Full Text] [Related]
17. Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue.
Alshaer MH; Barlow B; Maranchick N; Moser M; Gramss L; Burgmann H; Jalali VA; Wölfl-Duchek M; Jäger W; Poschner S; Plöchl W; Reinprecht A; Rössler K; Gruber A; Zeitlinger M; Peloquin CA; Hosmann A
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0043822. PubMed ID: 35862739
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
